For (ex)entrepreneurs, families, wealthy individuals, business professionals, healthcare professionals and executives.
For family offices, foundations & charities and independent asset managers.
For institutional and wholesale clients.
For corporates, institutional investors and private equity.
Private Banking & Wealth Management
Professional Solutions
Investment Management
Van Lanschot Kempen closely monitors markets and economic developments. Stay informed and up to date on current topics. Read our articles, watch our videos and listen to our podcasts.
Private Banking
Investment management
Investment banking
Read more about our organisation, news, investor relations and our contribution to a sustainable society.
Read more about working at Van Lanschot Kempen and view current vacancies.
Read more about Evi, our online investment coach.
Read more about our expertise and offices in different countries.
Are you already a client or interested in our services? We are happy to help you.
We are happy to speak to you in person. Call us or click on the link below for more contact options and locations.
The Netherlands
0800 17 37
Belgium
+32 (0)32 86 69 80
Switzerland
+41 (0)43 377 11 11
We are happy to speak to you in person. Call us or click on the link below for more contact options and locations.
The Netherlands
+31 (0)20 348 87 00
United Kingdom
+44 (0)20 36 36 94 00
France
+33 (0)18 375 62 73
We are happy to speak to you in person. Call us or click on the link below for more contact options and locations.
The Netherlands
+31 (0)20 348 80 00
United Kingdom
+44 (0)20 36 36 94 00
United States of America
+1 (0)21 237 601 34
Sequana Medical
Joint Global Coordinator and Joint Bookrunner
Kempen & Co acted as Joint Global Coordinator & Joint Bookrunner in the successful capital increase via Accelerated Bookbuild Offering of €22.5 million of Sequana Medical
Transaction highlights
- Capital increase by way of Accelerated Bookbuild Offering comprising 2,647,059 new shares, representing approximately 17% of the Company’s outstanding share capital
- The deal was priced at €8.50 per share, which is c. 42% above the offer price of Sequana Medical’s previous capital increase approximately one year ago
- The transaction launched following supportive market sounding and was upsized due to strong demand once in the market both by core existing and new investors, including European and US investors
- Net proceeds will be used to continue and advance the North American pivotal study of the alfapump® in liver disease, and the repeated dose study of the alfapump DSR® (Direct Sodium Removal) in diuretic-resistant heart failure patients
- This transaction represents the third transaction in which Kempen & Co acted as Joint Global Coordinator and Joint Bookrunner for the Company following a capital increase in 2020 and the IPO in early 2019, underpinning our ambition to be a long-term partner for our clients
- Moreover, Sequana Medical’s capital increase marks Kempen & Co’s 4th ECM transaction for a European Life Sciences company priced in 2021 year to date
Company description
Background Kempen Life Sciences & Healthcare
In the last twelve months, Kempen & Co has successfully completed a large number of transactions in its Life Sciences & Healthcare franchise. Recent transactions include:
- Co-Manager in the USD 115 million US Public Offering by Autolus Therapeutics
- Co-Manager in the USD 165 million Nasdaq Initial Public Offering by Pharvaris
- Passive Bookrunner in the USD 518 million US Public Offering by CureVac
- Lead Manager in the USD 120 million US Public Offering by Merus
- Financial Adviser to DCprime in its merger with Immunicum
- Joint Bookrunner in the SEK 564 million Capital Increase by Cantargia
- Sole Financial Adviser in the sale of Galapagos’ service operation, Fidelta, to Selvita for a total consideration of €31.2 million
- Placement Agent in Investinor’s Secondary Sell-Down of c. 4 million shares in Calliditas Therapeutics
- Lead Manager in the USD 85.0 million Nasdaq Initial Public Offering by Galecto
- Joint Bookrunner in the €31.0 million Capital Increase by Sensorion
- Bookrunner in the USD 245 million Nasdaq Initial Public Offering by Curevac
- Co-Manager in the USD 49.0 million US Public Offering by Centogene
- Joint Bookrunner in the SEK 1.11 billion Capital Increase by Hansa Biopharma
- Joint Bookrunner in the CHF 80.2 million Capital Increase by Molecular Partners
- Co-Manager in the USD 690 million US Public Offering by Ascendis Pharma
- Financial advisor in Immatics’ business combination with Arya Sciences Acquisition Corp., thereby becoming a Nasdaq listed company and securing USD 253 million
- Joint Global Coordinator and Joint Bookrunner in the €61.8 million Initial Public Offering by Hyloris Pharmaceuticals
- Joint Bookrunner in the €20.0 million Capital Increase by Oryzon Genomics
- Joint Global Coordinator and Joint Bookrunner in the SEK 487 million Capital Increase by BioInvent
- Joint Global Coordinator and Joint Bookrunner in the c. SEK 400 million Capital Increase by Immunovia